Tag: TNKase
Tenecteplase becomes first new stroke medicine to gain Health Canada approval...
Hoffmann-La Roche (Roche Canada) announced this week that Health Canada has granted market authorisation for its TNKase brand of tenecteplase—a thrombolytic agent—in the treatment...
TNKase gains US FDA approval for acute ischaemic stroke treatment
Genentech, a member of the Roche Group, has announced the US Food and Drug Administration (FDA) approval of the thrombolytic agent TNKase (tenecteplase) for the...
